Plain-English translation of NCT06482268 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new treatment called CT1-DAP001, which involves transplanting specially grown stem cells into a specific part of the brain. These stem cells are designed to produce dopamine, a chemical messenger that is lacking in people with Parkinson's disease. The trial will watch carefully for safety and also measure whether this treatment helps improve your Parkinson's symptoms.
Standard Parkinson's medications don't work well enough for everyone, and some people develop side effects over time. This trial exists to see whether introducing new dopamine-producing cells directly into the brain could offer a new way to treat the disease and improve quality of life for people who aren't getting adequate relief from current drugs.
You likely qualify if…
You likely don't qualify if…
You would undergo brain surgery to have the stem cells transplanted into a specific part of your brain called the corpus striatum. After the procedure, you would need to take immune-suppressing medication to help your body accept the new cells. You would return for multiple follow-up visits and tests over time so doctors can carefully monitor your safety and measure whether your Parkinson's symptoms improve.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
University of California, San Diego
Collaborators
Sumitomo Pharma America, Inc., Kyoto University
Enrollment target
~7 participants
Started
June 2024
Primary completion
February 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
40 Years – 75 Years
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Christian Fulinara
University of California, San Diego
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.